Thanks.As it turned out the CEO got back to me just about half...

  1. 2,833 Posts.
    lightbulb Created with Sketch. 471
    Thanks.

    As it turned out the CEO got back to me just about half an hour ago and was quite generous with his time and good to talk with. I was treated with respect..

    So I will summarize the main points we covered.

    1. The forecast of being cash flow positive is still in place and has not been withdrawn.

    2. The testosterone generic is selling but is currently supply constrained. After the launch they only really got the numbers from the manufacturer (which was originally expected to be in stock at the release date) by January of this year. The distributer is reluctant to take on bigger contracts on offer as not being able to deliver due to lack of supply will damage both the medication and the distributers relationships and are difficult to recover from. Some sales have occurred .

    3. In regard the Lidocaine 2.5%/Prilocaine 2.5% they have fairly advanced negotiations on a new distributer. Michael commented that they got the product back from Harris because the business was badly damaged by COVID and there was doubt over whether Harris could still deliver. Apparently the best quality staff were fleeing or about to flee as Harris sunk financially due to the pandemic - despite 19 straight years of profit before that. There is more than one distributer interested in the product but they have narrowed down to a preferred one at this stage.

    4. While the cash flow positive forecast is still in place, Michael said that making the forecast is dependent on some revenues coming in from the testosterone as well as the other existing sources of revenue.

    5. The Estrodial spray is a positive for the company. The deal that was done for US distribution included up front payments but the ongoing revenue is low and cant be re-negotiated. Sales are moribund. The distribution for the rest of the world particularly Europe has a higher royalty and is where the growth is. Patients who are prescribed the product tend to stay on it and its reputation in European is building but is a steady slow growth.

    So that's the main points. Good to have some facts which prevents assuming the worse. But it seems to me that cash flow positive is a fair ask from this point.





    Last edited by mwilson25: 25/02/22
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
-0.001(5.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
2.0¢ 2.0¢ 1.9¢ $13.72K 687.1K

Buyers (Bids)

No. Vol. Price($)
6 618035 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 10000 1
View Market Depth
Last trade - 14.19pm 18/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.